Study of AC-201 in Patients With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 259 participants.

Also called NCT01276106

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 259 participants (enrolled count) (from the registry)
Sponsor
TWi Biotechnology, Inc. (from the registry)
Registry
  • NCT NCT01276106
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01276106. Randomized; triple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-02 (actual). Results posted on 2014-11-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of AC-201 in Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
AC-201, 25mg
Intervention (Drug)
AC-201, 50mg
Intervention (Drug)
AC-201, 75mg
Intervention (Drug)
Placebo
Lead sponsor
TWi Biotechnology, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01276106
Content hash
5578edf2f80ed13dfa4cad559c4ce279d87ad8f03353f0f5381ea471f01d4f8d